December 18, 2018
Takeda Pharmaceutical said on December 17 that its antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) gained the backing of a key European panel for its use in combination with adriamycin, vinblastine, and dacarbazine (AVD) in adult patients with previously untreated CD30-positive...read more